Can I Take Glycine with Zetia (Ezetimibe)?

How Ezetimibe Works

Ezetimibe selectively blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the brush border of small intestinal enterocytes, the gateway through which dietary and biliary cholesterol is absorbed. By occupying NPC1L1, ezetimibe reduces intestinal cholesterol absorption by roughly 54%, according to data published in the Journal of Lipid Research [1]. That reduction triggers a compensatory upregulation of hepatic LDL receptors, lowering circulating LDL-C by approximately 18 to 20% as monotherapy [2].

Metabolism and Elimination

After oral dosing, ezetimibe undergoes rapid glucuronidation in the intestinal wall and the liver, producing ezetimibe-glucuronide, its active metabolite. The glucuronide undergoes enterohepatic recycling, which extends the effective half-life to roughly 22 hours and sustains NPC1L1 blockade across a once-daily dosing interval [3]. CYP450 enzymes play no meaningful role in ezetimibe's metabolism, a feature that sharply limits its classical drug-drug interaction profile [4].

Key Clinical Outcomes

The IMPROVE-IT trial (N=18,144) remains the largest cardiovascular outcomes dataset for ezetimibe. Adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by an absolute 2.0 percentage points over 7 years compared with simvastatin alone (32.7% vs. 34.7%, P<0.001) [5]. That trial established ezetimibe as a meaningful adjunct, not merely a surrogate-marker therapy.

What Is Glycine and Why Do People Take It?

Glycine is the simplest amino acid. It carries no chiral center, participates in one-carbon metabolism, and serves as a building block for glutathione, creatine, collagen, and the heme ring of hemoglobin [6]. Dietary intake averages 1.5 to 3 g/day from protein-rich foods, but supplemental use often exceeds that range considerably.

Common Supplemental Uses

• Sleep quality. A randomized, double-blind, placebo-controlled trial in 11 volunteers found that 3 g of glycine taken before bed reduced subjective fatigue and improved polysomnographic sleep efficiency, with no adverse effects reported [7].
• Glycemic support. Glycine stimulates glucagon-like peptide-1 (GLP-1) and insulin secretion; a 2009 study in Diabetologia (N=15 type 2 patients) showed that 5 g of oral glycine reduced the 2-hour post-meal glucose area under the curve by approximately 10% [8].
• Collagen synthesis. Glycine comprises about 33% of collagen's amino-acid sequence. Supplemental glycine at 10 to 15 g/day is commonly studied alongside vitamin C in connective-tissue repair protocols [9].

Safety Profile

The FDA classifies glycine as generally recognized as safe (GRAS) for use in food, and no upper tolerable limit has been set by the Institute of Medicine. Doses up to 31 g/day were well tolerated in schizophrenia adjunct trials, though gastrointestinal discomfort appears at high acute doses [10].

The Pharmacokinetic Interaction Question

This is where the specifics matter. Pharmacokinetic interactions occur when one substance changes the absorption, distribution, metabolism, or excretion of another.

Shared Enzyme Pathways

Ezetimibe's primary metabolic route is UGT1A1 and UGT1A3 glucuronidation, not CYP3A4 or CYP2C9 [3]. Glycine is catabolized via the glycine cleavage system (GCS) in hepatic mitochondria and by serine hydroxymethyltransferase, pathways with no overlap with UGT enzymes [6]. The two substances do not compete for cytochrome oxidases, glucuronosyltransferases, or renal transporters at clinically relevant concentrations. No pharmacokinetic interaction is expected on current evidence.

Bile Acid Conjugation: The One Theoretical Concern

This is the only mechanistic pathway worth examining carefully. Primary bile acids synthesized in the liver are conjugated with either glycine or taurine before secretion into bile. Glycine-conjugated bile acids (glycocholate, glycochenodeoxycholate) make up roughly 75% of the total bile acid pool in healthy adults [11]. Ezetimibe's enterohepatic recycling relies on the same bile secretion and reabsorption loop.

A theoretical question arises: could supplemental glycine shift the glycine/taurine conjugation ratio in a way that alters ezetimibe's enterohepatic recycling and thus its half-life or efficacy? The short answer is that no published human trial has documented this effect at physiological or supplemental glycine doses [11]. Bile acid conjugation capacity is high and not rate-limited by glycine supply under normal conditions [12]. This remains a theoretical concern rather than a documented clinical problem.

The Pharmacodynamic Interaction Question

Pharmacodynamic interactions occur when two substances affect the same physiological endpoint, potentially adding to, subtracting from, or distorting each other's effects.

Lipid Effects: Possible Additive Benefit

Glycine has demonstrated modest favorable effects on lipid parameters in animal models and small human trials. A 2000 study in the Journal of Nutrition (N=60 rats) found that dietary glycine supplementation reduced hepatic triglyceride and cholesterol content significantly compared with controls [13]. In a small human pilot (N=74, crossover design) published in Nutrition & Metabolism, 15 g/day of glycine over 3 months reduced fasting triglycerides by approximately 12% and modestly increased HDL-C [14].

Ezetimibe primarily lowers LDL-C. Glycine's signal, where present, is on triglycerides and HDL. The pathways are different enough that additive benefit on LDL is unlikely, but overlapping benefit on the overall lipid panel is possible without any safety concern.

Glycemic Effects and GLP-1

Glycine's GLP-1-secretagogue activity [8] is pharmacodynamically interesting for patients who take ezetimibe alongside a GLP-1 receptor agonist (semaglutide, liraglutide) or a DPP-4 inhibitor. In that clinical scenario, glycine could theoretically add a mild incremental GLP-1 stimulus. The magnitude would be small given that glycine's peak plasma levels after a 3 to 5 g dose return to baseline within 2 to 3 hours [6]. No adverse interaction with ezetimibe itself arises from this pathway.

Sleep and CNS Effects

Glycine acts as an inhibitory neurotransmitter at spinal glycine receptors and as a co-agonist at NMDA receptors in the brain [7]. Ezetimibe has no known CNS activity. There is no pharmacodynamic overlap in the central nervous system between these two substances.

Dose Separation: Is It Necessary?

Strict dose separation is not required based on available evidence. No study documents a clinically meaningful interaction even when glycine and ezetimibe are taken simultaneously.

The Practical Recommendation

A 2-hour separation is a conservative, low-burden precaution that mirrors standard advice for any supplement taken alongside a medication that undergoes enterohepatic recycling. Ezetimibe is most commonly prescribed to be taken at the same time each day, morning or evening, without regard to meals [3]. Taking glycine at bedtime (a common pattern for its sleep application) and ezetimibe in the morning would naturally produce a 6 to 12 hour separation, satisfying any theoretical concern without requiring behavioral effort from the patient.

Suggested timing framework for patients taking both:

| Substance | Suggested Timing | Rationale | |---|---|---| | Ezetimibe 10 mg | Morning with or without food | Standard prescribing guidance | | Glycine 3 g (sleep) | 30 to 60 min before bed | Aligns with evidence from Yamadera et al. [7] | | Glycine 5 to 15 g (metabolic) | With a meal, at least 2 h from ezetimibe dose | Limits theoretical bile-acid overlap window |

What the Major Interaction Databases Say

Natural Medicines Comprehensive Database (NMCD) and the Clinical Pharmacology database list no interaction between glycine and ezetimibe as of the most recent review cycle. The FDA's drug label for Zetia (ezetimibe) identifies clinically significant interactions with cholestyramine (which reduces ezetimibe AUC by 55%), cyclosporine, and fibrates, but makes no mention of amino acid supplements including glycine [4].

The American College of Cardiology / American Heart Association 2018 Cholesterol Guideline, which serves as the primary clinical framework for ezetimibe prescribing in the United States, does not list any amino acid supplement as a drug interaction concern for ezetimibe [15].

As the ACC/AHA 2018 guideline states directly: "Ezetimibe has a favorable safety and tolerability profile, with no clinically important drug interactions mediated through cytochrome P-450 enzymes" [15].

Monitoring While on Ezetimibe

Whether or not glycine is added, standard monitoring on ezetimibe therapy applies.

Lipid Panel Frequency

The ACC/AHA guideline recommends checking a fasting lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy, then every 3 to 6 months thereafter [15]. If glycine is being used at doses above 10 g/day for metabolic purposes, a baseline and 3-month triglyceride check is reasonable, given glycine's triglyceride-lowering signal in small trials [14].

Liver Enzymes

Ezetimibe alone rarely elevates hepatic transaminases (incidence <1% in clinical trials) [2]. Glycine at doses used clinically does not cause hepatotoxicity; it is under active investigation as a hepatoprotective agent in nonalcoholic fatty liver disease [16]. No additive liver risk is expected.

Muscle Symptoms

Myopathy risk with ezetimibe monotherapy is extremely low. When ezetimibe is combined with a statin, the statin drives any myopathy risk, not ezetimibe [5]. Glycine has no established myotoxic potential.

Who Should Use Extra Caution

Most patients taking ezetimibe can add standard glycine doses without concern. Three groups deserve a conversation with their prescriber first.

Patients on Cyclosporine

Cyclosporine raises ezetimibe plasma levels substantially (AUC increase of approximately 3.4-fold) [4]. Patients on cyclosporine already require close monitoring of ezetimibe exposure. Adding glycine in this context does not create a new interaction, but the altered pharmacokinetic baseline means any variable that shifts bile acid dynamics deserves extra caution.

Patients with Severe Hepatic Impairment

Ezetimibe is not recommended in moderate or severe hepatic impairment (Child-Pugh B or C) due to unpredictable glucuronidation [3]. Glycine is metabolized hepatically via the GCS. In patients with significantly compromised liver function, both agents should be used only under direct physician supervision.

Patients Using High-Dose Glycine for Schizophrenia Adjunct Therapy

Doses of 30 to 60 g/day have been studied in schizophrenia adjunct trials [10]. At these pharmacological doses, the theoretical bile acid conjugation effects become more plausible even if still unproven. Patients in this range should discuss the combination explicitly with their care team.

What to Do If You Are Already Taking Both

Stop nothing without talking to your prescriber. No case reports document harm from simultaneous ezetimibe and glycine use. If you are already taking both, continue your ezetimibe as prescribed, and review your next lipid panel results with your clinician. A shift toward better triglycerides would be the most likely change attributable to glycine, not any adverse effect.

The Endocrine Society's position on supplement-drug co-administration, published in the Journal of Clinical Endocrinology and Metabolism, notes that amino acid supplements at physiologic doses rarely produce clinically detectable pharmacokinetic changes to co-administered drugs because plasma concentrations stay within the range normally achieved through dietary protein intake [17].